VRSEF - Verisante Technology Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Verisante Technology Inc.

2639 Viking Way
Suite 140
Richmond, BC V6V 3B7
Canada
604-605-0507
http://www.verisante.com

Sector
Industry
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Thomas A. Braun BA, J.D., LLMChief Exec. Officer, Pres and Director251.46kN/A50
Ms. Anna Trinh B.Comm LLBChief Financial Officer, Corp. Counsel and Sec.133.02kN/A44
Mr. Rizah BahicExec. OfficerN/AN/AN/A
Amounts are as of December 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Verisante Technology Inc., a medical device company, engages in commercializing skin cancer detection systems. The company's products comprise Verisante Aura, which helps in the detection of various forms of skin cancer, including basal cell and squamous cell carcinoma, and melanoma; and Verisante Core for the detection of lung, cervical, gastrointestinal, and colo-rectal cancers. It also owns all the rights to the ClearVu and ClearVu Elite endoscopy systems for the detection of lung cancer. Verisante Technology has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. Verisante Technology Inc. was founded in 2006 and is based in Richmond, Canada.

Corporate Governance

Verisante Technology Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.